A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome

clinical trial

Details

Instance of: clinical trial
Start time: March 2020
End time: June 2022
Country: United States
Main subject: nephrotic syndrome, nephrosis, syndrome
clinical trial phase: phase I clinical trial
maximum age: 79
minimum age: 18
number of participants: 30
sponsor: University of North Carolina at Chapel Hill, American College of Clinical Pharmacy
study type: interventional study
title: A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome
uses: partial thromboplastin time

Nothing in the MetaHistoryBook collection references this item yet.